Compare UNH & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UNH | MRK |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.0B | 317.8B |
| IPO Year | 2010 | 1995 |
| Metric | UNH | MRK |
|---|---|---|
| Price | $365.13 | $143.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 28 |
| Target Price | ★ $481.72 | $154.62 |
| AVG Volume (30 Days) | 3.9M | ★ 5.2M |
| Earning Date | 10-13-2026 | 10-29-2026 |
| Dividend Yield | ★ 2.53% | 2.34% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 12.94 | N/A |
| Revenue | ★ $447,567,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | N/A | $3.29 |
| Revenue Next Year | $2.91 | $4.59 |
| P/E Ratio | $28.83 | ★ N/A |
| Revenue Growth | ★ 11.81 | 1.31 |
| 52 Week Low | $255.97 | $82.01 |
| 52 Week High | $461.62 | $157.00 |
| Indicator | UNH | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 37.03 | 46.44 |
| Support Level | $366.00 | $142.32 |
| Resistance Level | $405.64 | $153.19 |
| Average True Range (ATR) | 6.61 | 3.19 |
| MACD | -0.11 | -0.73 |
| Stochastic Oscillator | 20.21 | 18.84 |
UnitedHealth Group is one of the largest private health insurers and provides medical benefits to about 51 million members globally, including 1 million outside the US as of December 2025. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in medical insurance. Along with its insurance assets, UnitedHealth's Optum franchises help create a healthcare services colossus that spans everything from pharmaceutical benefits to providing outpatient care and analytics to affiliates and third parties.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).